MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
33.37
-0.10
-0.30%
Opening 14:00 09/04 EDT
OPEN
33.28
PREV CLOSE
33.47
HIGH
33.73
LOW
33.18
VOLUME
8.94K
TURNOVER
--
52 WEEK HIGH
44.00
52 WEEK LOW
17.00
MARKET CAP
131.95M
P/E (TTM)
-31.6064
1D
5D
1M
3M
1Y
5Y
1D
vTv Therapeutics initiated with an Outperform at LifeSci Capital
TipRanks · 2d ago
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT)
TipRanks · 2d ago
Weekly Report: what happened at VTVT last week (0824-0828)?
Weekly Report · 4d ago
Weekly Report: what happened at VTVT last week (0817-0821)?
Weekly Report · 08/24 09:01
Weekly Report: what happened at VTVT last week (0810-0814)?
Weekly Report · 08/17 09:01
Weekly Report: what happened at VTVT last week (0803-0807)?
Weekly Report · 08/10 09:01
Analysts Conflicted on These NA Names: LATAM Airlines Group SA Sponsored ADR (LTM), vTv Therapeutics (VTVT) and Once Upon a Farm, PBC (OFRM)
TipRanks · 08/10 08:01
vTv Therapeutics (VTVT) Gets a Buy from Roth MKM
TipRanks · 08/07 12:37
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Webull offers vTv Therapeutics Inc stock information, including NASDAQ: VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.